Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer

Liu, Yanyan; Zhang, Guoxiu; Li, Haiyan; Han, Lihong; Fu, Aiguo; Zhang, Nali; Zheng, Youguang

doi:10.1016/j.biopha.2015.07.026

Cited by 21 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 25 Compared with intracellular miRNAs, biofluid miRNAs are non-invasive biomarkers for clinical application in cancer. For example, serum miR-30e and miR-223 can be used to distinguish hepatocellular carcinoma from healthy controls; 26 the expression of serum miR-365 was related to the overall survival of patients with lung cancer; 27 and the serum expression levels of miR-21, miR-17 and miR-92 were highly correlated with recurrence after adjuvant chemotherapy in patients with colon cancer. 28 …”

Section: Micrornas Are Emerging Biomarkers For Cancermentioning

confidence: 99%

MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer

Yuan

Wang

Zhang

2018

OTT

View full text Add to dashboard Cite

Despite the widespread use of endoscopy and conventional tumor biomarkers, gastric cancer (GC) remains one of the most frequent causes of cancer-related deaths worldwide due to its late diagnosis and poor response to treatment. Valuable and practical biomarkers are urgently needed to screen patients with a high risk of GC that can complement endoscopic diagnosis. Such biomarkers will enable the efficient prediction of therapeutic response and prognosis of GC patients and favor the establishment of an effective treatment strategy for each and every patient. MicroRNAs (miRNAs) are a class of small non-coding RNA sequences that play important roles in modulating key biological processes by regulating the expression of target genes. Expectedly, miRNAs are abnormally expressed within the tumor tissue and in associated biological fluids of GC patients including their blood, gastric juice, and urine. Accumulating evidence indicates that miRNAs are potential biomarkers with multiple diagnostic functions for GC. Here, we review recent advances and challenges in using miRNAs, particularly biofluid miRNAs, as GC biomarkers with potential clinical applications including diagnosing, clinically staging, and predicting malignant behaviors, therapy response, recurrence after surgery and survival time.

show abstract

Section: Micrornas Are Emerging Biomarkers For Cancermentioning

confidence: 99%

MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer

Yuan

Wang

Zhang

2018

OTT

View full text Add to dashboard Cite

show abstract

“…For example, serum miRNA-30e and miRNA-223 are useful diagnostic biomarkers for hepatocellular carcinoma [14]. Serum miRNA-365 expression correlates with overall survival of patients with non-small cell lung cancer [15]. Serum expression levels of miRNA-17, miRNA-21, and miRNA-92 predict recurrence after adjuvant chemotherapy in colon cancer patients [16].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer

Hou

Luo

2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Aims: Recent studies have demonstrated that microRNAs (miRNAs) can serve as useful biomarkers for human cancers. The aim of this study was to evaluate the expression level of serum miRNA-206 in patients with gastric cancer (GC) and investigate its diagnostic and prognostic value. Methods: Quantitative real-time PCR was performed to evaluate serum miRNA-206 levels in 150 GC patients and 150 healthy volunteers. The association between miRNA-206 expression and clinicopathological factors as well as patient's survival was analyzed. Receiver operator curve (ROC) analysis was carried out to assess the potential value of serum miRNA-206 for GC diagnosis. Results: Serum miRNA-206 was down-regulated in GC patients compared with healthy controls (P < 0.001). Decreased serum miRNA-206 expression was significantly associated with deep local invasion, positive lymph node metastasis, and advanced clinical stage. Serum miRNA-206 expression was found to be significantly up-regulated in paired post-operative samples and reduced in patients with GC recurrence. ROC curve analysis showed that serum miRNA-206 was a useful marker for GC diagnosis, and could discriminate between recurred and non-recurred patients. Multivariate Cox regression analysis confirmed low serum miRNA-206 expression as an independent unfavorable prognostic factor for both DFS and OS of GC patients. Conclusions: These results suggest that serum miRNA-206 might not only serve as a novel diagnostic biomarker for GC, but also predict cancer recurrence and patient's prognosis.

show abstract

“…Furthermore, miR-365-3p has been reported to serve as a therapeutic biomarker for various cancers and tumors such as lung cancer [39,40], colon cancer [28], pancreatic cancer [41], breast cancer [42] and gastric tumorigenesis [43]. Moreover, miR-365-3p inhibited vascular smooth muscle cell proliferation through targeting of CCND1 [44].…”

Section: The Expression Pro Le and Functional Roles Of Bta-mir-365-3pmentioning

confidence: 99%

MicroRNA bta-miR-365-3p inhibits proliferation but promotes differentiation of primary bovine myoblasts by targeting the activin A receptor type I

Hao¹,

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: MicroRNAs act as post-transcriptional regulators that repress translation or degrades mRNA transcripts. Each microRNA has many mRNA targets and each mRNA may be targeted by several microRNAs. Skeletal muscles express a plethora of microRNA genes that regulate muscle development and function by controlling the expression of protein-coding target genes. To expand our understanding of the role of microRNA, specifically bta-miR-365-3p, in muscle biology, we studied its function in regulating primary bovine myoblast proliferation and differentiation.Results: We first show that bta-miR-365-3p is predominantly expressed in skeletal muscle and heart tissue in Chinese Qinchuan beef cattle. Quantitative PCR and western blotting showed that overexpression of bta-miR-365-3p significantly reduced the levels of cyclinD1 (CCND1), cyclin dependent kinase 2 (CDK2) and proliferating cell nuclear antigen (PCNA) but stimulated the expression of muscle differentiation markers MYOD1, MYOG, both at mRNA and protein level. Moreover, downregulation of bta-miR-365-3p increased the expression of CCND1, CDK2 and PCNA but decreased the expression of MYOD1 and MYOG at both mRNA and protein levels. Furthermore, flow cytometry, EdU proliferation assays and immunostaining showed that increased levels of bta-miR-365-3p suppressed cell proliferation but promoted myotube formation, whereas a decreased level of bta-miR-365-3p had opposite consequences. Finally, we determined that activin A receptor type I (ACVR1) is a direct target of bta-miR-365-3p. Thus, dual luciferase gene reporter assays demonstrated that bta-miR-365-3p can bind to the 3'UTR of ACVR1 gene to regulate its expression. Consistently, knock-down of ACVR1 was associated with reduced CDK2, CCND1 and PCNA expression but increased MYOG and MYOD1 expression both at mRNA and protein level.Conclusion: Collectively these data suggest that bta-miR-365-3p represses proliferation but promotes differentiation of bovine myoblasts through a mechanism involving downregulation of ACVR1.

show abstract

Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer

Cited by 21 publications

References 28 publications

MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer

MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer

Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer

MicroRNA bta-miR-365-3p inhibits proliferation but promotes differentiation of primary bovine myoblasts by targeting the activin A receptor type I

Contact Info

Product

Resources

About